Researchers conducted a prospective, longitudinal cohort study involving individuals with current or former habit, who had ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung ... the subtype of cancer, and the stage at diagnosis. When considering the 5-year survival rate for ...
New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...
Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...
Checkmate 816 established chemoimmunotherapy as the standard of care neoadjuvant treatment for resectable stage ... phase III trial schema. ECOG PS, Eastern Cooperative Oncology Group performance ...
TAGRISSO plus savolitinib showed durable response rates in lung cancer patients with ... global Phase III trial in patients with unresectable, Stage III EGFRm NSCLC whose disease has not ...
Evidence of the beneficial effect of lung cancer screening by low-dose chest CT scans on lung cancer mortality reduction in a ...
Annual lung cancer screening, or LCS, detects cancer at a higher rate and at earlier stages, findings suggest.According to Roger Y. Kim, MD, MSCE, DAABIP, ATSF, an assistant professor of medicine at ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback